Donor CD30.CAR-EBVST in Patients with Relapsed or Refractory CD-30 Positive Lymphomas

Inclusion Criteria

• Diagnosis and clinical course falling into one of the following categories: * Hodgkin lymphoma: ** Refractory to second line chemotherapy ** Relapsed or progressive after high dose therapy/autologous stem cell transplantation ** Relapsed or progressive after treatment with brentuximab or a checkpoint inhibitor * Aggressive non-Hodgkin lymphoma: * Refractory to second line chemotherapy * Relapsed or progressive after high dose therapy/autologous stem cell transplantation * Anaplastic lymphoma kinase (ALK)-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma: ** Refractory to first line chemotherapy ** Relapsed after first line therapy (possibly including high dose therapy/autologous stem cell transplantation) * ALK-positive anaplastic T cell lymphoma: ** Refractory to second line therapy ** Relapsed after second line therapy
• CD30-positive tumor as assayed in a Clinical Laboratory Improvement Act (CLIA) certified pathology laboratory
• Age 12 to 75 years
• Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal
• Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
• Estimated glomerular filtration rate (GFR) > 70 mL/min
• Pulse oximetry of > 90% on room air
• Electrocardiogram (EKG) shows no significant arrhythmias as be determined at the investigators’ discretion
• Karnofsky or Lansky score of > 60
• Available allogeneic T cells with >= 15% expression of CD30CAR determined by flow cytometry
• Recovered from all acute non-hematologic toxic effects of all prior chemotherapy
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom
• Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form

Exclusion Criteria

• Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
• Received CD30 antibody-based therapy within the previous 4 weeks
• Received gemcitabine-containing chemotherapy within the previous 12 weeks
• History of hypersensitivity reactions to murine protein-containing products
• Pregnant or lactating
• Tumor in a location where enlargement could cause airway obstruction (determined at the investigators’ discretion)
• Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg/day of prednisone
• Active significant, uncontrolled bacterial, viral or fungal infection
• Symptomatic cardiac disease (New York Heart Association [NYHA] Class III or IV disease)